Promising combo tackles FLT3 leukemia in early trial
NCT ID NCT03900949
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether adding two targeted drugs, gemtuzumab ozogamicin and midostaurin, to standard chemotherapy is safe for people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that has a FLT3 mutation. The trial enrolled 21 adults and aimed to find the best dose with acceptable side effects. The goal is to improve initial treatment for this hard-to-treat leukemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gemtuzumab ozogamicin and midostaurin combined with standard chemotherapy (cytarabine and daunorubicin)
- What this could lead to
- If successful, this could lead to a more effective initial treatment for a specific type of AML, potentially improving remission rates.
- What could go wrong
- This is a very early (Phase I) safety study with only 21 participants. The combination may cause severe side effects and may not improve outcomes in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Oregon Health and Science University Knight Cancer Institute - Northwest Portland
Portland, Oregon, 97210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?